Development of influenza A antivirals

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S204100, C424S209100, C435S006120, C435S029000, C435S235100, C514S888000

Reexamination Certificate

active

07601490

ABSTRACT:
The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.

REFERENCES:
patent: 2005/0191703 (2005-09-01), Palese et al.
patent: 2005/0233963 (2005-10-01), Moseley et al.
Salvatore and Garcia-Sastre. Virus versus host: modulation of the host a/b interferon pathways by the inf luenza A virus NS1 protein. International Congress Series 1219 (2001) 513-520.
Yoneyama, et al. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. The EMBO Journal. 1998, vol. 17 No. 4 pp. 1087-1095.
Ohnishi, et al. Mechanism of Host Defense Suppression Induced by Viral Infection: Mode of Action of Inosiplex as an Antiviral Agent. Infection and Immunity, Oct. 1982, vol. 38, No. 1: p. 243-250.
Barabino, S. M., et al., “The 30-kD subunit of mammalian cleavage and polyadenylation specificity factor and its yeast homolog are RNA-binding zinc finger proteins.” Genes Dev (1997), 11:1703-16.
CDC (Center for Disease Control). 2005. Key facts about influenza and the influenza vaccine. http://www.cdc.gov/flu/keyfacts.htm.
Chen, Z., Y. Li, et al., “Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3′-end processing machinery.” EMBO J (1999), 18:2273-83.
Cox, N. J., et al., “Influenza.” Lancet (1999), 354:1277-82.
Ferguson, N. M., et al., “Strategies for containing an emerging influenza pandemic in Southeast Asia.” Nature (2005), 437:209-14.
Geiss, G. K., et al., “Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza.” Proc Natl Acad Sci U S A (2002), 99:10736-41.
Kim, M. J., et al., “Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique.” Proc Natl Acad Sci U S A (2002), 99:10096-101.
Kiso, M., K. et al., “Resistant influenza A viruses in children treated with oseltamivir: descriptive study.” Lancet (2004), 364:759-65.
Le, Q. M., et al., “Avian flu: isolation of drug-resistant H5N1 virus.” Nature (2005), 437:1108.
Li, Y., et al., “The 3′-end-processing factor CPSF is required for the splicing of single-intron pre-mRNAs in vivo.” RNA (2001), 7:920-31.
Longini, I. M., Jr., et al., “Containing pandemic influenza at the source.” Science (2005), 309:1083-7.
Longtine, M. S., et al., “Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae.” Yeast (1998), 14:953-61.
Nemeroff, M. E., et al., “The influenza virus NS1 protein forms multimers in vitro and in vivo.” Virology (1995), 212:422-8.
Nemeroff, M. E., et al., “Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3′end formation of cellular pre-mRNAs.” Mol Cell (1998), 1:991-1000.
Noah, D. L., et al., “Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS.” Virology (2003), 307:386-95.
Puthavathan, P., et al., “Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand.” J Gen Virol (2005), 86:423-33.
Qiu, Y., et al., “The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A).” J Virol (1994), 68:2425-32.
Reid, A. H., et al., “The 1918 Spanish influenza: integrating history and biology.” Microbes Infect (2001), 3:81-87.
Shimizu, K., A. Iguchi, R. Gomyou, and Y. Ono. 1999. Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Virology (1999), 254:213-9.
Suzuki, H., et al., “Emergence of amantadine-resistant influenza A viruses: epidemiological study.” J Infect Chemother (2003), 9:195-200.
Yuan, W., et al., “Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein.” EMBO J (2001), 20:362-71.
International Search Report and Written Opinion for PCT/US2006/046234 dated Dec. 21, 2007.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Development of influenza A antivirals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Development of influenza A antivirals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of influenza A antivirals will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4065302

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.